Moreover, as far as cryptococcal infection prevention in HIV-infected patients is considered a recent study in Uganda showed that initial CRAG screening prior to starting ART in patients with CD4+ count ≤100 cells/μl is cost-effective; the number of patients needed to test and treat with CRAG screening and fluconazole to save 1 life was estimated 15.9 and the costs at $266 [13]. The gene discussed is CD4; the disease is cryptococcosis.